Xigduo (dapagliflozin and metformin extended-release) / AstraZeneca 
Welcome,         Profile    Billing    Logout  
 5 Diseases   6 Trials   6 Trials   135 News 
8 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Xigduo (dapagliflozin and metformin extended-release) / AstraZeneca
NCT02911792: Effect of Farxiga on Renal Function and Size in Type 2 Diabetic Patients With Hyperfiltration

Completed
4
72
US
Dapagliflozin, Farxiga, Metformin, Metformin-XR, Glipizide 5 MG
The University of Texas Health Science Center at San Antonio, AstraZeneca
Diabetes Mellitus, Type 2
07/23
07/23
NCT03710460: Effect of Dapagliflozin/Metformin XR vs Monotherapies on Anthropometric Indicators in Obesity

Recruiting
4
33
RoW
Dapagliflozin, Forxiga, Dapagliflozin plus Metformin XR, XigDuo, Metformin XR
University of Guadalajara
Obesity
12/23
12/23
NCT06327815: Efficacy of FDC Regimen of Dapagliflozin/Metformin Compared to Co-administered Dual Therapy on Glycemic Control, Satisfaction and Adherence in Chinese Patients With T2DM

Active, not recruiting
4
632
RoW
Xigduo (Dapagliflozin and Metformin hydrochloride extended-release) tablets, FDC Regimen of Dapagliflozin/Metformin XR, Dapagliflozin tablets and Metformin HCl extended-release tablets, Co-administered Dual Therapy
AstraZeneca
Type 2 Diabetes Mellitus (T2DM)
06/25
06/25
NCT05601336: of Sodium Glucose Cotransporter-2 Inhibitors on Metabolic, Hormonal and Clinical Parameters in PCO

Recruiting
3
200
RoW
Dapagliflozin 5 MG, [Farxiga], Metformin Hydrochloride 1000 MG, Glucophage 1000mg, Dapagliflozin/Metformin, Xigduo
Beni-Suef University
PCO
07/23
07/23
NCT06405178: Adjuvant Therapy With Letrozole in Induction of Ovulation With Polycystic Ovarian Syndrome

Not yet recruiting
3
500
RoW
Metformin, Glucophage 1000, Dapagliflozin, Forxiga, Dapagliflozin/Metformin, Xigduo, Letrozole, femara
Beni-Suef University
Polycystic Ovary
12/24
12/24
NCT07026968: A Study of Prusogliptin Tablets Combined With Dapagliflozin Tablets and Metformin Hydrochloride Extended Release Tablets in Type 2 Diabetes

Not yet recruiting
3
815
NA
Prusogliptin, Dapagliflozin(high dose), Dapagliflozin (low dose) placebo, plus metformin XR, Prusogliptin placebo, Dapagliflozin(high dose), Dapagliflozin (low dose) placebo, plus metformin XR, Prusogliptin, Dapagliflozin(high dose) placebo, Dapagliflozin (low dose), plus metformin XR, Prusogliptin placebo, Dapagliflozin (high dose) placebo, Dapagliflozin (low dose), plus metformin XR, Prusogliptin, Dapagliflozin (high dose) placebo, Dapagliflozin(low dose) placebo, plus metformin XR
CSPC Ouyi Pharmaceutical Co., Ltd.
Type 2 Diabetes
10/26
11/26
EPIK-B4, NCT04899349: Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER2-, Advanced Breast Cancer While on Treatment With Alpelisib and Fulvestrant

Terminated
2
2
US, RoW
Alpelisib, Fulvestrant, Metformin XR, Dapagliflozin + metformin XR, Dapagliflozin
Novartis Pharmaceuticals
Breast Cancer
05/23
05/23
SOLDMiDiab02, NCT05477017: Evaluation of SGLT2-i Effectivness and Safety in Elderly Type 2 Diabetes Patients

Not yet recruiting
N/A
800
Europe
SGLT2 inhibitor, Jardiance, Synjardy, Forxiga, Xigduo, Invokana, Vokanamet, Steglatro, Segluromet
University of Milan
Type2Diabetes
12/22
03/23
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Xigduo (dapagliflozin and metformin extended-release) / AstraZeneca
NCT02911792: Effect of Farxiga on Renal Function and Size in Type 2 Diabetic Patients With Hyperfiltration

Completed
4
72
US
Dapagliflozin, Farxiga, Metformin, Metformin-XR, Glipizide 5 MG
The University of Texas Health Science Center at San Antonio, AstraZeneca
Diabetes Mellitus, Type 2
07/23
07/23
NCT03710460: Effect of Dapagliflozin/Metformin XR vs Monotherapies on Anthropometric Indicators in Obesity

Recruiting
4
33
RoW
Dapagliflozin, Forxiga, Dapagliflozin plus Metformin XR, XigDuo, Metformin XR
University of Guadalajara
Obesity
12/23
12/23
NCT06327815: Efficacy of FDC Regimen of Dapagliflozin/Metformin Compared to Co-administered Dual Therapy on Glycemic Control, Satisfaction and Adherence in Chinese Patients With T2DM

Active, not recruiting
4
632
RoW
Xigduo (Dapagliflozin and Metformin hydrochloride extended-release) tablets, FDC Regimen of Dapagliflozin/Metformin XR, Dapagliflozin tablets and Metformin HCl extended-release tablets, Co-administered Dual Therapy
AstraZeneca
Type 2 Diabetes Mellitus (T2DM)
06/25
06/25
NCT05601336: of Sodium Glucose Cotransporter-2 Inhibitors on Metabolic, Hormonal and Clinical Parameters in PCO

Recruiting
3
200
RoW
Dapagliflozin 5 MG, [Farxiga], Metformin Hydrochloride 1000 MG, Glucophage 1000mg, Dapagliflozin/Metformin, Xigduo
Beni-Suef University
PCO
07/23
07/23
NCT06405178: Adjuvant Therapy With Letrozole in Induction of Ovulation With Polycystic Ovarian Syndrome

Not yet recruiting
3
500
RoW
Metformin, Glucophage 1000, Dapagliflozin, Forxiga, Dapagliflozin/Metformin, Xigduo, Letrozole, femara
Beni-Suef University
Polycystic Ovary
12/24
12/24
NCT07026968: A Study of Prusogliptin Tablets Combined With Dapagliflozin Tablets and Metformin Hydrochloride Extended Release Tablets in Type 2 Diabetes

Not yet recruiting
3
815
NA
Prusogliptin, Dapagliflozin(high dose), Dapagliflozin (low dose) placebo, plus metformin XR, Prusogliptin placebo, Dapagliflozin(high dose), Dapagliflozin (low dose) placebo, plus metformin XR, Prusogliptin, Dapagliflozin(high dose) placebo, Dapagliflozin (low dose), plus metformin XR, Prusogliptin placebo, Dapagliflozin (high dose) placebo, Dapagliflozin (low dose), plus metformin XR, Prusogliptin, Dapagliflozin (high dose) placebo, Dapagliflozin(low dose) placebo, plus metformin XR
CSPC Ouyi Pharmaceutical Co., Ltd.
Type 2 Diabetes
10/26
11/26
EPIK-B4, NCT04899349: Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER2-, Advanced Breast Cancer While on Treatment With Alpelisib and Fulvestrant

Terminated
2
2
US, RoW
Alpelisib, Fulvestrant, Metformin XR, Dapagliflozin + metformin XR, Dapagliflozin
Novartis Pharmaceuticals
Breast Cancer
05/23
05/23
SOLDMiDiab02, NCT05477017: Evaluation of SGLT2-i Effectivness and Safety in Elderly Type 2 Diabetes Patients

Not yet recruiting
N/A
800
Europe
SGLT2 inhibitor, Jardiance, Synjardy, Forxiga, Xigduo, Invokana, Vokanamet, Steglatro, Segluromet
University of Milan
Type2Diabetes
12/22
03/23

Download Options